Site icon pharmaceutical daily

Global Epilepsy Pipeline Landscape Report 2021: Comprehensive Insights for 70+ Companies and 70+ Pipeline Drugs – ResearchAndMarkets.com

BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Epilepsy – Pipeline Insight, 2021” clinical trials has been added to ResearchAndMarkets.com’s offering.

This Epilepsy – Pipeline Insight, 2021 provides comprehensive insights about 70+ companies and 70+ pipeline drugs in Epilepsy pipeline landscape.

It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Epilepsy R&D. The therapies under development are focused on novel approaches to treat/improve Epilepsy.

Epilepsy Emerging Drugs Chapters

This segment of the Epilepsy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Epilepsy Emerging Drugs

GWP42003-P: GW Research

Epidiolex (formerly, GWP42003-P) is an oral cannabidiol solution that GW Pharmaceuticals developed. The U.S. Food and Drug Administration (FDA) approved it to treat seizures in patients with Dravet syndrome and Lennox-Gastaut syndrome age 1 and older. Epidiolex is a plant-derived cannabidiol, a non-psychoactive marijuana extract. It is currently being investigated in Phase III clinical trial to treat Epilepsy.

Ganaxolone: Marinus Pharmaceuticals

Ganaxolone is a GABAA receptor modulator that acts by regulating brain activity is being evaluated in Phase III stage of development. This process can include inhibiting the abnormal electrical discharges that cause seizures and status epilepticus or restoring balance in disrupted neuronal activity in other CNS disorders.

Because ganaxolone modulates both synaptic and extrasynaptic GABAA receptors and is unique relative to other approved antiepileptic drugs, we believe it has the potential to treat seizures resistant to other available medications. These binding sites, including the extrasynaptic GABAA receptor, may also be important in treating status epilepticus and other brain disorders.

XEN496: Xenon Pharmaceuticals

XEN496, a Kv7 potassium channel modulator that is a proprietary pediatric formulation of the active ingredient ezogabine being developed for the treatment of KCNQ2 developmental and epileptic encephalopathy (KCNQ2-DEE). With the U.S. Food and Drug Administration (FDA) having completed its review of the clinical trial protocol, Xenon is on track to initiate the XEN496 Phase 3 clinical trial in pediatric patients with KCNQ2-DEE.

In addition, Xenon has received a positive opinion from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA), which recommends the granting of an orphan medicinal product designation for XEN496 for the treatment of KCNQ2-DEE. This European designation is in addition to the FDA granting Fast Track designation for XEN496 for the treatment of seizures associated with KCNQ2-DEE as well as Orphan Drug Designation (ODD) for the treatment of KCNQ2-DEE.

CVL-865: Cereval therapeutics

The positive allosteric modulator (PAM) of GABAA channels, CVL-865 has been shown in a phase II trial to have pronounced anticonvulsant activity in patients with photosensitive epilepsy, with efficacy similar to lorazepam. CVL-865 acts at GABAA channels with a2, a3, and a5 subunits, known to have anticonvulsant (a2 only), analgesic, anxiolytic, and muscle-relaxing properties from GABAergic PAMs. It is hoped that CVL-865, by selectively modulating a2, a3, and a5 will enable higher receptor occupancy than can be achieved with non-selective benzodiazepines and achieve seizure suppression with greater tolerability owing to fewer sedative or cognitive effects.

ES-481: ES Therapeutics

ES-481 is being developed by ES Therapeutics for the treatment of Epilepsy. ES therapeutics is conducting Phase IIA single-arm exploratory clinical study in up to 12 adult subjects aged 18 and older with primary glioma, IDH1 mutation, and uncontrolled focal-onset seizure activity to determine the potential efficacy, safety and pharmacokinetics of ES-481 as adjunctive therapy in glioma-associated epilepsy and to assess for potential anti-tumorigenic effects.

Major Players in Epilepsy

There are approx. 70+ key companies which are developing the therapies for Epilepsy. The companies which have their Epilepsy drug candidates in the most advanced stage, i.e. Phase III include, GW Research.

Key Questions Answered

Key Topics Covered:

Introduction

Executive Summary

Epilepsy: Overview

Pipeline Therapeutics

Therapeutic Assessment

Late Stage Products (Phase III)

GWP42003-P: GW Research

Mid Stage Products (Phase II)

CVL-865: Cereval therapeutics

Early stage products (Phase I)

OPC-214870: Otsuka Pharmaceutical

Inactive Products

Epilepsy Key Companies

Epilepsy Key Products

Epilepsy-Unmet Needs

Epilepsy Market Drivers and Barriers

Epilepsy Future Perspectives and Conclusion

Epilepsy Analyst Views

Epilepsy Key Companies

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/6iou1c

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Exit mobile version